Cardiovascular | iPharmaCenter

Novartis’ Fabhalta Demonstrates Improved Hemoglobin Levels in PNH Patients Switching from Anti-C5 Therapy | iPharmaCenter

Novartis has announced positive results from the Phase IIIB APPULSE-PNH study, highlighting the effectiveness of Fabhalta (iptacopan), an...

Janssen Pharmaceutical has updated the Phase 3 MACiTEPH study, which evaluates macitentan 75mg in patients with Chronic Thromboembolic...

Bayer presented the long-term studies of Xarelto in patients with coronary artery disease and/or peripheral artery disease. Bayer has...